Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432027 | 0.84 | ALDH1A1 (0.53) | BCHECNR1CNR2SLC6A2SLC6A3 | |
| SCHEMBL2341659 | 0.84 | ALDH1A1 (0.53) | BCHECNR1CNR2SLC6A2SLC6A3 | |
| SCHEMBL1046242 | 0.83 | F10 (0.47) | BCHE | |
| SCHEMBL1326645 | 0.79 | CNR1 (0.49) | BCHECNR1CNR2SLC6A2SLC6A3 | |
| SCHEMBL1328117 | 0.78 | BCHE (0.43) | BCHESLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL24671736 | 0.77 | BCHE (0.50) | BCHECNR1CNR2SLC6A2SLC6A3 | |
| SCHEMBL2838917 | 0.77 | HDAC4 (0.58) | BCHECNR1SLC6A2SLC6A3HDAC3 | |
| SCHEMBL24671773 | 0.77 | BCHE (0.50) | BCHECNR1CNR2SLC6A2SLC6A3 | |
| SCHEMBL18978359 | 0.76 | BCHE (0.55) | BCHEMEN1KMT2A | |
| SCHEMBL11096414 | 0.74 | KMT2A (0.61) | BCHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | claimed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | claimed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | claimed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | claimed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | YALE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2358750-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010053584-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN3, KCNN4, KCNMA1 | BCHE 4323/4885CNR1 924/4885CNR2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.